NBIX - Neurocrine announces FDA approval of INGREZZA (valbenazine) capsules
2023-08-18 17:34:51 ET
More on Neurocrine Biosciences
Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts
Neurocrine Biosciences, Inc. 2023 Q2 - Results - Earnings Call Presentation
Neurocrine Biosciences, Inc. ( NBIX ) Q2 2023 Earnings Call Transcript
Neurocrine Biosciences: In Limbo Until The Arrival Of The 'Next Big Thing' Beyond Ingrezza
Eli Lilly, Merck among top pharma picks in Barclays Q2 preview
BMO upgrades Neurocrine to market perform on Ingrezza outlook
Neurocrine sees August FDA action date for valbenazine for chorea
For further details see:
Neurocrine announces FDA approval of INGREZZA (valbenazine) capsules